<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/003812CD-18CA-4415-85A0-D112873B652B"><gtr:id>003812CD-18CA-4415-85A0-D112873B652B</gtr:id><gtr:name>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/740EC483-DF48-408C-BA1F-0510D198296F"><gtr:id>740EC483-DF48-408C-BA1F-0510D198296F</gtr:id><gtr:name>School of Biology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:department>Sch of Engineering and Physical Science</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/003812CD-18CA-4415-85A0-D112873B652B"><gtr:id>003812CD-18CA-4415-85A0-D112873B652B</gtr:id><gtr:name>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/740EC483-DF48-408C-BA1F-0510D198296F"><gtr:id>740EC483-DF48-408C-BA1F-0510D198296F</gtr:id><gtr:name>School of Biology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A2084609-314E-41CE-AD86-E4B5D596E089"><gtr:id>A2084609-314E-41CE-AD86-E4B5D596E089</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:otherNames>Reid</gtr:otherNames><gtr:surname>Leslie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D25E5CC6-E888-4C36-B940-B2FC4C764251"><gtr:id>D25E5CC6-E888-4C36-B940-B2FC4C764251</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Downes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801865"><gtr:id>5C42A629-FC32-4303-A24C-3B5C97E3EE89</gtr:id><gtr:title>Antagonism of PI 3-kinase signalling by PTEN and SHIP2</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801865</gtr:grantReference><gtr:abstractText>The human body is made up of cells which form the tissues and organs. The different tissues of the body have developed to perform specialised functions which must be coordinated for the organism as a whole to function efficiently and survive. Cell signalling is the process by which cells in our bodies communicate with one another and signal transduction is the means by which a specific signal (perhaps a hormone, such as insulin), arriving at its target tissue, is interpreted to elicit a particular response. Defects in cell signalling are common causes of important human diseases such as cancer and diabetes. We are studying the details of a signal transduction process which malfunctions in more than 50% of human tumours and which accounts for many of the effects of insulin produced after a meal. The central character of this response is a fatty substance or lipid called PIP3 which is made by enzymes called PI 3-kinases. When this substance is produced at the correct time, in the right part of the cell and in small, but sufficient amounts it triggers normal cell responses, but too much, in the wrong place or at an inappropriate time can lead to or promote the development of a tumour. On the other hand, producing too little in response to insulin can be a cause of diabetes. Maintaining this delicate balance of PIP3 involves the PI 3-kinase enzymes which make PIP3 and enzymes called phosphatases which remove it. We are studying the factors which regulate two classes of PIP3 phosphatase called PTEN and SHIP2. PTEN is a tumour suppressor that is mutated or absent in many different kinds of human tumour. We use tissue culture cells to study PTEN and SHIP2 regulation and epithelial cells (the source of most solid tumours) as simple models of disease to examine the consequences of defects in PIP3 phosphatase activity. Lastly, we are developing unique mouse models harbouring specific defects in the PTEN gene to validate the physiological significance of our work using cultured cells. Because of its importance in human disease many pharmaceutical companies are developing drugs which block the PI 3-kinase signalling pathway including inhibitors, currently in clinical trials as anti-cancer or anti-inflammatory agents, of PI 3-kinases themselves. My group has a longstanding, active collaboration with a consortium of 5 international companies to accelerate their drug discovery endeavours in this field.</gtr:abstractText><gtr:technicalSummary>Class I phosphoinositide 3-kinases (PI 3-kinases) synthesise phosphatidylinositol 3,4,5-trisphosphate (PtdInsP3), a lipid second messenger which controls cell growth, motility, survival and metabolism in response to a wide variety of hormonal and environmental cues. Defects in this regulatory system contribute to the pathology of important human diseases including many forms of cancer, type II diabetes and inflammatory disorders. The integrity of PI 3-kinase signalling depends upon the correct temporal and spatial distribution of inositol lipid second messengers determined by the regulation and targeting of Class I PI 3-kinases and PtdInsP3 phosphatases. Moreover, the metabolism of PtdInsP3 serves at least two distinct purposes. Firstly, the termination of PtdInsP3 signalling via removal of the 3-phosphate by the tumour suppressor phosphatase, PTEN. Secondly, the co-ordinated synthesis of additional lipid signals, including phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) and phosphatidylinositol 3-phosphate via removal of the 5-phosphate by one or more members of the phosphoinositide 5-phosphatase family such as SHIP and SHIP2. Whilst the functions and molecular targets of PtdInsP3 are well understood, the relative contributions of PtdInsP3 and/or PtdIns(3,4)P2 to PI 3-kinase signalling and which, if any of these functions are driven primarily by PtdIns(3,4)P2 remain ill-defined. We aim to develop our understanding of the distinct biological functions of PtdInsP3 metabolism under four thematic headings. (i) How do cells exert independent temporal and spatial control of PtdInsP3 versus PtdIns(3,4)P2 when the latter is a metabolic product of the former? (ii) The identification, characterisation and biological functions of PtdIns(3,4)P2 effector proteins. (iii) The roles of PTEN and SHIP2 in the development and maintenance of cell polarity in epithelial cells and other relevant models. How does loss of PTEN or oncogenic mutation of p110alpha affect PtdInsP3 distribution and cell polarity? (iv) What, if any, is the role of PTEN s specificity for both PtdInsP3 and phosphopeptide substrates in mediating its tumour suppressor function? Our approach is multidisciplinary, involving molecular characterisation of expressed and purified components; studies of endogenous and exogenously expressed components in cell lines, 3D epithelial cell cultures and other model systems; and the generation of unique mouse models arising from original discoveries in our laboratory concerning substrate recognition by PTEN. We will continue to collaborate with major pharmaceutical companies via the Division of Signal Transduction Therapy of which CPD is a co-director and which aims to accelerate drug discovery in the area of protein and lipid kinases and phosphatases.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2451411</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life Sciences</gtr:department><gtr:description>Academic collaboration - Doreen Cantrell</gtr:description><gtr:id>256D7C5C-9A5F-45D3-AD4F-FE43D1D6EBB3</gtr:id><gtr:impact>Unpublished data</gtr:impact><gtr:partnerContribution>Expertise in T-cell biology and oncogenesis2 .Transgenic mouse lines required for T-cell specific manipulation of Pten. One postdoc working part-time on the project.</gtr:partnerContribution><gtr:piContribution>3 transgenic mouse lines with mutations at the Pten locus. Expertise in the analysis of Pten function. One of the postdocs working part-time on the project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Biomolecular Sciences; University of St Andrews</gtr:department><gtr:description>Acadamic collaboration - Rick Randall</gtr:description><gtr:id>67B4AAC9-6F1D-4BE9-96D4-48C19E705C09</gtr:id><gtr:impact>Publications: PM ID: 18029356 and 20133840</gtr:impact><gtr:partnerContribution>Sharing unpublished data</gtr:partnerContribution><gtr:piContribution>Sharing data and analysing samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heriot-Watt University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering &amp; Physical Sciences</gtr:department><gtr:description>Academic collaboration - Rory Duncan</gtr:description><gtr:id>C80F71AA-B726-4ACE-9993-8ADA9C197CF7</gtr:id><gtr:impact>Funding for 2 studentships, both started in 2013</gtr:impact><gtr:partnerContribution>Prof Duncan provides expertise in super-resolution imaging and the use of fluorescent probes to investigate molecular interactions in living and fixed cells.</gtr:partnerContribution><gtr:piContribution>Two PhD students are being co-supervised by myself and Prof Duncan. One is principally supervised by me and funded by a Heriot Watt University studentship. The other student is funded by a large collaborative MRC grant (ESRIC) and is executing a collaboration between my lab and those of Prof Duncan (HWU) and Ted Hupp at the Edinburgh University Cancer Centre. My lab provides research expertise in cancer biology and signal transduction.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medicine, Dentistry &amp; Nursing</gtr:department><gtr:description>Academic collaboration - Seth Schorr</gtr:description><gtr:id>22C9C693-2732-49A5-B573-21DBE265EC14</gtr:id><gtr:impact>Publication: Ellis et al, PMID: 20600851</gtr:impact><gtr:partnerContribution>Extensive experimnetal collaboration, significant scientific dialog, and experiments mostly performed by rsesearchers funded from collaborators lab.</gtr:partnerContribution><gtr:piContribution>Project instigation and direction. Some experiments. Writing and over-seeing publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Commercial service collaboration - Novartis</gtr:description><gtr:id>419D845C-3DC3-488B-8D83-F1198B1701DD</gtr:id><gtr:impact>We obtained scientifically valuable data from several control compounds and supplied data to Novartis regarding their test compounds.</gtr:impact><gtr:partnerContribution>It motivated us to test several control compounds as inhibitors of the tumour suppressor phosphatase PTEN</gtr:partnerContribution><gtr:piContribution>We tested several compounds for their ability to inhibit PTEN in vitro</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Life Sciences</gtr:department><gtr:description>Academic collaboration - Grahame Hardie</gtr:description><gtr:id>FC66F99F-8BE0-41F4-9F22-39C7298508BC</gtr:id><gtr:impact>Co-authored research paper positively reviewed at the Biochemical journal and currently being revised.</gtr:impact><gtr:partnerContribution>Expertise and reagents to study the regulation of AMP-Kinase. Most of the researcher time committed to this project.</gtr:partnerContribution><gtr:piContribution>Expertise in manipulating cellular PI3K/PTEN signalling. Cell lines and reagents.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Developmental Neurobiology</gtr:department><gtr:description>Academic collaboration - Britta Eickholt</gtr:description><gtr:id>58425AC6-C222-4BF0-AA82-3D6744DCE193</gtr:id><gtr:impact>3 research Publications: 
PubMed IDs: 19767745, 23940795, 23085752</gtr:impact><gtr:partnerContribution>The Eickholt lab have provided reagents and shared unpublished data to allow collaborative projects. They also hosted an NRL lab postdoctoral researcher working in the Eickholt lab in Berlin for 2 months in 2013</gtr:partnerContribution><gtr:piContribution>Extensive academic collaboration, involving reagent exchange, sharing ideas and data. One postdoctoral researcher worked in the Eickholt lab in Berlin for 2 months in 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DSTT Pharameutical Consortium</gtr:description><gtr:id>F27C7CE7-57C1-45A0-87B7-87A8CC3243F0</gtr:id><gtr:impact>The collaboration has supported the drug discovery efforts of 6 major global pharmaceutical companies in the field of PI 3-Kinase signalling, an extrememly active area, especially for cancer. The collaboration has supported 2 or 3 research posts in the core CPD/NRL labs since its inception in 1998 contributing to many of the CPD lab publications over this time. It has also funded a level of around ten active laboratory positions since 1998, with these trained staff going into further academic and commercial positions.</gtr:impact><gtr:partnerContribution>We have had occasional access to novel compounds from these pharmaceutical collaborators for use as experimental enzyme inhibitors in our research. Extensive interactions with the pharmaceutical collaborators has also been effectiove in broadening the translational training of the research team.</gtr:partnerContribution><gtr:piContribution>The collaboration is funded by a pharmaceutical consortium, supporting several activities including a research Division sited in the University of Dundee College of Life Sciences. From 1998-2012 this was overseen by the co-directors, Peter Downes, the original PI on this grant and Professors Philip Cohen and Dario Alessi. Dr Leslie and Prof Downes and their research groups also provided advice and expertise to the consortium companies. Since the last renewal of the collaboration in 2012, the grant holders have not been formally involved but occasionally act as informal consultants to the consortium companies, the last instance being in October 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Academic collaboration - Britta Eickholt</gtr:description><gtr:id>77894F97-E002-424D-A6BC-2175B26D4709</gtr:id><gtr:impact>3 research Publications: 
PubMed IDs: 19767745, 23940795, 23085752</gtr:impact><gtr:partnerContribution>The Eickholt lab have provided reagents and shared unpublished data to allow collaborative projects. They also hosted an NRL lab postdoctoral researcher working in the Eickholt lab in Berlin for 2 months in 2013</gtr:partnerContribution><gtr:piContribution>Extensive academic collaboration, involving reagent exchange, sharing ideas and data. One postdoctoral researcher worked in the Eickholt lab in Berlin for 2 months in 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School and early undergraduate project placements</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>50CE7979-507C-4C2E-AEA1-EA995134E708</gtr:id><gtr:impact>We regularly host laboratory placements for school and early undergraduate students to experience research

To my knowledge, all of these students have entered University scientific degree programmes or in the case of relevant undregraduates continued a research/scientific career</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press and media coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AAD9A86A-2270-45FF-BF0A-BE7FB4C5A034</gtr:id><gtr:impact>Peter Downes and Nick Leslie have been interviewed by press and television to discuss individual research publications.

MRC funded work in the CPD/NRL laboratory is also of great interest to the pharmaceutical industry and underpined the ground breaking collaboration between Dundee scientists and five leading pharmaceutical companies known as the Division of Signal Transduction Therapy (DSTT). Peter Downes was a founding co-director of DSTT which has attracted much external interest 1998-2012. During the period of support we have hosted at least eight visits from members of the international press and other publishing activities, Scottish and international development agencies and industry.

Elevated profile of MRC funded research and its translation to drug discovery through collaboration with global pharmaceutical companies. The PI3K pathway which is the subject of this funding and which was co-discovered by Peter Downes, is one of the most fertile areas of mechanism based drug dicovery, especially relating to human cancer.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>College Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1FEA40E4-677A-40F3-B8E8-9FFD11454FAF</gtr:id><gtr:impact>Several group members presenting science at College Open Day

High attendence (around 300)</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV and radio interviews (Brain Tumour Charity)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E704CA6-AE71-49F7-832C-8CF9654BF980</gtr:id><gtr:impact>Interviews broadcast by BBC Radio and ITV TV news discussing 3D bioprinting research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AICR Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2650C535-43AA-44D6-B644-567193EEFC9C</gtr:id><gtr:impact>Public Open Day organised by Association for Cancer Research

Raising awareness of research. Donations to medical resaerch</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DSTT Pharmaceutical Consortium</gtr:description><gtr:fundingOrg>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:fundingOrg><gtr:id>0E4509D5-A7D9-445B-B684-BDC39A8D8EB4</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heriot Watt University 'Theme Studentship'</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Heriot-Watt University</gtr:fundingOrg><gtr:id>101C880A-DDA6-45EF-BD3E-EE8A79E36C05</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust 4yr PhD studentship programme</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>95CB554C-907B-4ABD-8B09-2E2707F7E426</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112439</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRS 4yr Studentship</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:fundingRef>PhD-1034-2106</gtr:fundingRef><gtr:id>D7FEEC18-1B13-45A1-8E56-F8C0A27456B5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC DTA Quota 4yr studentship</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>3DDF8B71-F789-4D5E-A92B-5F7E17D95317</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust clinical PhD studentship programme</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EB565028-1CF7-404A-B5CC-046EC4EB0B0D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300626</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PrCa UK Project Grant</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG14-006</gtr:fundingRef><gtr:id>2A8931DA-EB00-482A-9A2A-25EDCD3A8288</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>163720</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project Grant</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>1F7942C5-39A7-4996-90DC-A50882539A94</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCUK Dorothy Hodgkin Studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Research Councils UK (RCUK)</gtr:fundingOrg><gtr:id>9C13AED2-6D48-4150-9145-7DDDBF8D81D0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Studentship (Bohringer Ingelheim)</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>4BC06C19-52CE-4F9B-A19F-48FBFF6352B3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>James Watt Studentship</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Heriot-Watt University</gtr:fundingOrg><gtr:id>783F6114-D15E-4CA6-AB59-5342ABF563C8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66924</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Ideas Award</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>The Brain Tumour Charity</gtr:fundingOrg><gtr:fundingRef>GN-000344</gtr:fundingRef><gtr:id>43F5A152-30A5-429B-B9D9-4FC680EEBD8A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The development of a lipid kinase selectivity screen is not strictly a discovery, but it requires a high level of expertise and reputation in the lipid signalling field as well as the resources required to generate large quantities of many enzymes grouped together under a single assay platform. We also have 'first mover' advantage in terms of the marketability of the screen and existing collaborators in the form of the DSTT member pharmaceutical companies.</gtr:description><gtr:id>91A1AC16-3216-46CE-9083-74BBAD7EAA19</gtr:id><gtr:impact>A screen which supports and drives PI 3-kinase pathway drug discovery within 5 major pharmaceutical companies.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Lipid kinase selectivity screen</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An extensive range of expression constructs (plasmids and viral vectors) for use in several systems.</gtr:description><gtr:id>B501D90F-27EE-4E8A-9984-DC375ABD726A</gtr:id><gtr:impact>We frequently supply other academic research groups with expression constructs (approx 10-15 times per year). Some of these interactions take the forms of collaborations, others simply acknowledged reagent supply. These reagents have been used in many subsequent published projects.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression construct collection</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This is a service provided to our pharmaceutical collaborators and the broader academic community supporting drug discovery efforts in the area of PI3K. It is the first of its kind developed within an academic setting.</gtr:description><gtr:id>64BBE382-E29C-49F6-A4C8-58A1190F47D1</gtr:id><gtr:impact>Supports intensive research in 5 global pharmaceutical companies developing novel cancer treatments targeting the PI 3-kinase pathway. Will develop a large data matrix relating compound structures to efficacy against a large number of lipid kinase enzymes.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Lipid Kinase selectivity screen</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.kinase-screen.mrc.ac.uk/kinase-lipid-kinase-panel</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Purified polyclonal antibodies produced during research programme</gtr:description><gtr:id>BF426AF6-7E4E-40F9-AB4C-A63360F20AD4</gtr:id><gtr:impact>Research publications and progress</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8EFB32B3-DC1A-4094-B559-C1E57B787096"><gtr:id>8EFB32B3-DC1A-4094-B559-C1E57B787096</gtr:id><gtr:title>A screen for novel phosphoinositide 3-kinase effector proteins.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10c5072ac3714a910a28244aeee2b690"><gtr:id>10c5072ac3714a910a28244aeee2b690</gtr:id><gtr:otherNames>Dixon MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65C96770-91BE-41B8-AA1F-70DC26979C6C"><gtr:id>65C96770-91BE-41B8-AA1F-70DC26979C6C</gtr:id><gtr:title>Non-genomic loss of PTEN function in cancer: not in my genes.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83603B83-DEE7-4C1E-AE59-E4E24212EA97"><gtr:id>83603B83-DEE7-4C1E-AE59-E4E24212EA97</gtr:id><gtr:title>Controlling PTEN (Phosphatase and Tensin Homolog) Stability: A DOMINANT ROLE FOR LYSINE 66.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3C5B7BB-D5B4-4070-8611-2FBC62EF902B"><gtr:id>C3C5B7BB-D5B4-4070-8611-2FBC62EF902B</gtr:id><gtr:title>Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.</gtr:title><gtr:parentPublicationTitle>Advances in biological regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2212-4926</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49B50A8B-569C-47E0-A80B-5C0A06875268"><gtr:id>49B50A8B-569C-47E0-A80B-5C0A06875268</gtr:id><gtr:title>Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/006ba0dc1da4463f740972bda069132f"><gtr:id>006ba0dc1da4463f740972bda069132f</gtr:id><gtr:otherNames>Davidson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/020D3C79-23E7-49E9-9B9F-7325C55C5A07"><gtr:id>020D3C79-23E7-49E9-9B9F-7325C55C5A07</gtr:id><gtr:title>Phosphorylation by Akt within the ST loop of AMPK-a1 down-regulates its activation in tumour cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db24d3db848e4c98b39f02c2e4938b1c"><gtr:id>db24d3db848e4c98b39f02c2e4938b1c</gtr:id><gtr:otherNames>Hawley SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9546B5D5-2931-4DF7-8C1A-8AA4D6104E4A"><gtr:id>9546B5D5-2931-4DF7-8C1A-8AA4D6104E4A</gtr:id><gtr:title>Class I PI 3-kinases: Function and evolution.</gtr:title><gtr:parentPublicationTitle>Advances in biological regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d7ef60b3194f22d59b92452b1508d92"><gtr:id>8d7ef60b3194f22d59b92452b1508d92</gtr:id><gtr:otherNames>Kriplani N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2212-4926</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/204655BD-CE0C-4461-BC98-5782BE8C091A"><gtr:id>204655BD-CE0C-4461-BC98-5782BE8C091A</gtr:id><gtr:title>Cell biology. Where is PTEN?</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91409AFB-B814-4E94-A2BC-48979F2EE6E6"><gtr:id>91409AFB-B814-4E94-A2BC-48979F2EE6E6</gtr:id><gtr:title>Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DA1402C-3813-4D4C-9B7F-1C948EDDF76A"><gtr:id>8DA1402C-3813-4D4C-9B7F-1C948EDDF76A</gtr:id><gtr:title>Activity of any class IA PI3K isoform can sustain cell proliferation and survival.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/feaeb1b73f83de9d7c3eae4d3152e7ac"><gtr:id>feaeb1b73f83de9d7c3eae4d3152e7ac</gtr:id><gtr:otherNames>Foukas LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57D74561-6D86-403A-A6B1-1C8234204A77"><gtr:id>57D74561-6D86-403A-A6B1-1C8234204A77</gtr:id><gtr:title>Inherited PTEN mutations and the prediction of phenotype.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/340FAE70-108A-4625-97BD-66A50904E235"><gtr:id>340FAE70-108A-4625-97BD-66A50904E235</gtr:id><gtr:title>Leptin regulates AMPA receptor trafficking via PTEN inhibition.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b776dfe698d77f95889b417812608a15"><gtr:id>b776dfe698d77f95889b417812608a15</gtr:id><gtr:otherNames>Moult PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F8AB7A7-4820-46FE-9E38-D02DDF422EA0"><gtr:id>6F8AB7A7-4820-46FE-9E38-D02DDF422EA0</gtr:id><gtr:title>A unified nomenclature and amino acid numbering for human PTEN.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e1e3224399b58a9b915fc1df0dd0fa39"><gtr:id>e1e3224399b58a9b915fc1df0dd0fa39</gtr:id><gtr:otherNames>Pulido R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27FDB9A5-DAB5-4922-95CD-0762A528EC8F"><gtr:id>27FDB9A5-DAB5-4922-95CD-0762A528EC8F</gtr:id><gtr:title>Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2972a1d230c58c4c94c46c30481045d9"><gtr:id>2972a1d230c58c4c94c46c30481045d9</gtr:id><gtr:otherNames>Turban S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B5D1FD38-DB42-4386-BB59-3E591B13FBAE"><gtr:id>B5D1FD38-DB42-4386-BB59-3E591B13FBAE</gtr:id><gtr:title>Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6fa4e8e0c4dd125db4bee84dfdc71abd"><gtr:id>6fa4e8e0c4dd125db4bee84dfdc71abd</gtr:id><gtr:otherNames>Hale BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29CAABB6-AA95-4474-BEBD-751ADBC5A61B"><gtr:id>29CAABB6-AA95-4474-BEBD-751ADBC5A61B</gtr:id><gtr:title>Three-dimensional bioprinting of complex cell laden alginate hydrogel structures.</gtr:title><gtr:parentPublicationTitle>Biofabrication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8633f08cf17357d1a4dcf9848456da4"><gtr:id>c8633f08cf17357d1a4dcf9848456da4</gtr:id><gtr:otherNames>Tabriz AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1758-5082</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F45581A-898D-445B-8787-CBAB75E5D5C5"><gtr:id>1F45581A-898D-445B-8787-CBAB75E5D5C5</gtr:id><gtr:title>Phosphorylation of the actin binding protein Drebrin at S647 is regulated by neuronal activity and PTEN.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a9f8ce8e3bcf8053dda802e2796f5a5"><gtr:id>1a9f8ce8e3bcf8053dda802e2796f5a5</gtr:id><gtr:otherNames>Kreis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/668ECAE9-AAF0-4DBA-AD80-D6B0E70A298E"><gtr:id>668ECAE9-AAF0-4DBA-AD80-D6B0E70A298E</gtr:id><gtr:title>Assaying PTEN catalysis in vitro.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC4AAC95-C677-4A83-8190-706B10123827"><gtr:id>FC4AAC95-C677-4A83-8190-706B10123827</gtr:id><gtr:title>MyosinV controls PTEN function and neuronal cell size.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b569d3769fdd6f083933ef62744f7a5"><gtr:id>7b569d3769fdd6f083933ef62744f7a5</gtr:id><gtr:otherNames>van Diepen MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00FC83B5-220A-4169-A6B3-D81801E19B0A"><gtr:id>00FC83B5-220A-4169-A6B3-D81801E19B0A</gtr:id><gtr:title>PDK1 controls upstream PI3K expression and PIP3 generation.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e75e89b85be0dbf75f79bd670c148841"><gtr:id>e75e89b85be0dbf75f79bd670c148841</gtr:id><gtr:otherNames>Dieterle AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D0E2F78-C941-452E-9D84-CEE8B2AF4874"><gtr:id>2D0E2F78-C941-452E-9D84-CEE8B2AF4874</gtr:id><gtr:title>PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1c632d4d5818f6265883ac8b204baaa"><gtr:id>c1c632d4d5818f6265883ac8b204baaa</gtr:id><gtr:otherNames>Gericke A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/60D437B4-286B-4B93-AE47-948DB706D063"><gtr:id>60D437B4-286B-4B93-AE47-948DB706D063</gtr:id><gtr:title>MC1R is a potent regulator of PTEN after UV exposure in melanocytes.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2d9388530a23d77d80cd9d8c73f76a35"><gtr:id>2d9388530a23d77d80cd9d8c73f76a35</gtr:id><gtr:otherNames>Cao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDE8EEDA-BDF4-42DB-AB47-8E2E571091C3"><gtr:id>EDE8EEDA-BDF4-42DB-AB47-8E2E571091C3</gtr:id><gtr:title>The PTEN and Myotubularin phosphoinositide 3-phosphatases: linking lipid signalling to human disease.</gtr:title><gtr:parentPublicationTitle>Sub-cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a3e892c4b10d0ee9cecc17dc1a7f6fbf"><gtr:id>a3e892c4b10d0ee9cecc17dc1a7f6fbf</gtr:id><gtr:otherNames>Davies EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-0225</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74F88AE0-4B3D-4C23-AAE7-068449A37D7E"><gtr:id>74F88AE0-4B3D-4C23-AAE7-068449A37D7E</gtr:id><gtr:title>Both p110a and p110? isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3e8c6e5c59dcda0e22861fa0587971f"><gtr:id>b3e8c6e5c59dcda0e22861fa0587971f</gtr:id><gtr:otherNames>Berenjeno IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D6A4CF1-4635-4621-8470-DDD9C57BC712"><gtr:id>4D6A4CF1-4635-4621-8470-DDD9C57BC712</gtr:id><gtr:title>A fluorescence lifetime-based assay for serine and threonine kinases that is suitable for high-throughput screening.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7ef8c36f8ae319b09dc632c5c38e824"><gtr:id>b7ef8c36f8ae319b09dc632c5c38e824</gtr:id><gtr:otherNames>Paterson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BAC2C11-DEF4-45DB-9DDB-F784CCDB03E5"><gtr:id>0BAC2C11-DEF4-45DB-9DDB-F784CCDB03E5</gtr:id><gtr:title>Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e20049003ad5f3ff9b43abc03cd978a7"><gtr:id>e20049003ad5f3ff9b43abc03cd978a7</gtr:id><gtr:otherNames>Rodr?guez-Escudero I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D87EE8D9-01B3-4980-847A-C0DD9D0B7EF5"><gtr:id>D87EE8D9-01B3-4980-847A-C0DD9D0B7EF5</gtr:id><gtr:title>Mutant PTEN in Cancer: Worse Than Nothing.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A2EA462-2072-4CB5-A383-7F74BEFF7E4F"><gtr:id>0A2EA462-2072-4CB5-A383-7F74BEFF7E4F</gtr:id><gtr:title>PTEN inhibitors: an evaluation of current compounds.</gtr:title><gtr:parentPublicationTitle>Advances in biological regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2212-4926</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/612A91A5-DC4D-4699-A588-CEAF52C4A6D7"><gtr:id>612A91A5-DC4D-4699-A588-CEAF52C4A6D7</gtr:id><gtr:title>Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3680b3b9762e33c97e20feae25aa79a5"><gtr:id>3680b3b9762e33c97e20feae25aa79a5</gtr:id><gtr:otherNames>Maccario H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/515DBC59-9D2E-46A3-9C3E-2A8EC076A0C5"><gtr:id>515DBC59-9D2E-46A3-9C3E-2A8EC076A0C5</gtr:id><gtr:title>PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4261451fb9912c6a602ad8d818b81701"><gtr:id>4261451fb9912c6a602ad8d818b81701</gtr:id><gtr:otherNames>Tibarewal P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68EFEE02-E088-4EEB-A9CA-E5CC4C42DCC1"><gtr:id>68EFEE02-E088-4EEB-A9CA-E5CC4C42DCC1</gtr:id><gtr:title>Mechanism of activation of PKB/Akt by the protein phosphatase inhibitor Calyculin A.</gtr:title><gtr:parentPublicationTitle>Cell biochemistry and biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/585617eaa3947795ff0812199452f105"><gtr:id>585617eaa3947795ff0812199452f105</gtr:id><gtr:otherNames>Pozuelo-Rubio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1085-9195</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB49A812-5323-4DB2-8744-5BDE7A300B7F"><gtr:id>DB49A812-5323-4DB2-8744-5BDE7A300B7F</gtr:id><gtr:title>Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71199c576f86dc8873643b3f7f6cd728"><gtr:id>71199c576f86dc8873643b3f7f6cd728</gtr:id><gtr:otherNames>Wullschleger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E8E9E8F8-E3DB-4B51-B76E-2E34BE4FA2CB"><gtr:id>E8E9E8F8-E3DB-4B51-B76E-2E34BE4FA2CB</gtr:id><gtr:title>C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate 1 (IRS-1), regulating IRS-1 stability and muscle atrophy.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06bc32a47baeb1b459cc91f7b75e152c"><gtr:id>06bc32a47baeb1b459cc91f7b75e152c</gtr:id><gtr:otherNames>Koh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC4398DA-939E-4F88-940F-D3F73EBD96FD"><gtr:id>DC4398DA-939E-4F88-940F-D3F73EBD96FD</gtr:id><gtr:title>Cross talk between the Akt and p38a pathways in macrophages downstream of Toll-like receptor signaling.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a421ad3f54cb2085f40ce1aa163aada7"><gtr:id>a421ad3f54cb2085f40ce1aa163aada7</gtr:id><gtr:otherNames>McGuire VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE891EC8-8DE9-4155-8084-5550D9D829F8"><gtr:id>BE891EC8-8DE9-4155-8084-5550D9D829F8</gtr:id><gtr:title>In Cell and In Vitro Assays to Measure PTEN Ubiquitination.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77F7994B-5A32-4E16-8700-F0E66AED08D4"><gtr:id>77F7994B-5A32-4E16-8700-F0E66AED08D4</gtr:id><gtr:title>Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9712998a8e9e09ad720a8a51a65ba01a"><gtr:id>9712998a8e9e09ad720a8a51a65ba01a</gtr:id><gtr:otherNames>Ellis IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5469554E-908C-45C7-B0EE-95C463D6FDBA"><gtr:id>5469554E-908C-45C7-B0EE-95C463D6FDBA</gtr:id><gtr:title>IQGAP proteins reveal an atypical phosphoinositide (aPI) binding domain with a pseudo C2 domain fold.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10c5072ac3714a910a28244aeee2b690"><gtr:id>10c5072ac3714a910a28244aeee2b690</gtr:id><gtr:otherNames>Dixon MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E23CDD7D-450F-49F2-B961-E32E646E6851"><gtr:id>E23CDD7D-450F-49F2-B961-E32E646E6851</gtr:id><gtr:title>PTEN: an intercellular peacekeeper?</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/613EB15A-E331-405C-A22F-7D6E5E53B0E0"><gtr:id>613EB15A-E331-405C-A22F-7D6E5E53B0E0</gtr:id><gtr:title>Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110a/PIK3CA but not by HER2 or mutant AKT1.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb6178f3d8f8a863ab7fdd12cb72e4b1"><gtr:id>eb6178f3d8f8a863ab7fdd12cb72e4b1</gtr:id><gtr:otherNames>Berglund FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801865</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>